OXiGENE's business strategy is to identify and in-license complimentary compounds from academic institutions, lead the compounds through early- to mid-stage clinical trials, and establish strategic partnerships with pharmaceutical and biotechnology companies to further develop, manufacture, and commercialize the compound. OXiGENE is pursuing an aggressive development plan to broaden the indication of use for current products and to bring new products into the clinic.
OXiGENE believes this business model:
Reduces costs,
Accelerates the drug development cycle,
Broadens the life cycle of products, and
Maximizes flexibility in the rapidly changing field of biotechnology.
